Lek Pharmaceuticals D.d.

Lek, Tovarna Farmacevtskih in Kemicnik Izdelkov

Natasa H Milac

Anton Copar

Uros Urleb

Barbara Podobnik

Darja Jereb

Andreja C Belcic

Sandi Borisek

Boris Rusjakovski

Alenka Kosak

Igor Langof

Brina Ornik

A novel crystalline form of the substrate known under the chemical name 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny]-1H-benzimidazole, and having the generic name omeprazole, hereinafter referred to as omeprozole form C, is disclosed. Further, a process for the preparation of omeprazole form C, a pharmaceutical formulation containing omeprazole form C in admixture with pharmaceutically acceptable excipients and the use of omeprazole form C for treatment of gastrointestinal disorders are disclosed.

Crystalline form of omeprazole

A new and improved process for the preparation of ceftriaxon disodium salt hemiheptahydrate of formula I ##STR1## is described, wherein 7-amino-3-{[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-as-triazin-3-yl)thio]met hyl}-3-cephem-4-carboxylic acid disodium salt is converted with a reactive 2-(2-aminothiazol-4-yl)-2-syn-metoxyimino acetic acid derivative such as 2-benzo-thiazolyl-thio ester in a water solution and in the presence of a suitable inert organic solvent such as acetone, at a temperature between 0.degree. C. and 40.degree. C. and then the desired compound is isolated in a very pure form and with a high total yield. Ceftriaxon is a cephalosporin antibiotic of the third generation for parenteral application and a valuable agent for the treatment of heavy infections.

Process for the preparation of ceftriaxon disodium salt hemiheptahydrate

Growing community of inventors

Ljubljana, Slovenia

Natasa H Milac